Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies), By Region, and Competition, 2019-2029F
Global Acute Myeloid Leukemia Market was valued at USD 0.75 billion in 2023 and is anticipated t%li%witness an impressive growth in the forecast period with a CAGR of 8.70% through 2029.
Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. It is characterized by the rapid growth of abnormal myeloid cells, which are immature white blood cells responsible for fighting infections and carrying oxygen. In AML, these abnormal cells d%li%not mature properly and crowd out healthy cells in the bone marrow, leading t%li%a decrease in the production of normal blood cells. This can result in a variety of symptoms and complications. AML can cause a range of symptoms, including fatigue, weakness, anemia (low red blood cell count), increased susceptibility t%li%infections, bleeding or bruising easily (due t%li%low platelet count), fever, and weight loss. Some patients may als%li%experience bone pain. The development of new and improved therapies, including targeted therapies and immunotherapies, has expanded the treatment options available for AML patients. These advancements provide more effective and personalized treatment approaches.
Ongoing research and development efforts in the field of AML have led t%li%the discovery of novel therapeutic targets and treatment strategies. This innovation attracts investment and drives the market forward. Advances in molecular diagnostics have enabled the identification of specific genetic mutations and markers associated with AML. This has paved the way for personalized treatment approaches, increasing the demand for targeted therapies. Regulatory agencies approving new therapies for AML treatment contribute t%li%market growth by expanding the available treatment options and improving patient outcomes. Improved awareness of AML symptoms and the importance of early diagnosis has led t%li%more patients seeking treatment at an earlier stage, potentially improving outcomes, and driving demand for therapies.
Key Market Drivers
Advancements in Treatment Options
The development of targeted therapies that focus on specific genetic mutations or molecular markers associated with AML has been a breakthrough. Drugs like 'FLT3 inhibitors' and 'IDH inhibitors' target specific mutations in leukemia cells, leading t%li%more effective and tailored treatments. Immunotherapies, including monoclonal antibodies and checkpoint inhibitors, are being explored for their potential in AML treatment. These therapies harness the body's immune system t%li%recognize and attack leukemia cells. The rise of precision medicine involves tailoring treatment based on a patient's unique genetic and molecular profile. This approach allows for personalized treatment strategies that have the potential t%li%be more effective and less toxic.
Epigenetic changes play a significant role in AML development. Drugs that target these changes, such as 'DNMT inhibitors' and 'HDAC inhibitors,' are being studied as potential treatments. Venetoclax, an inhibitor of BCL-2, has shown promise in combination with other therapies, particularly in older adults or those with certain genetic mutations. Advances in detecting very low levels of leukemia cells, known as MRD, have allowed for more accurate assessment of treatment response and adjustment of treatment strategies accordingly. Techniques for stem cell transplantation have improved, expanding the eligibility criteria, and reducing complications associated with the procedure. Researchers are investigating various combinations of chemotherapy, targeted therapies, and immunotherapies t%li%enhance treatment efficacy while minimizing side effects. Advances in supportive care, such as anti-nausea medications and infection prevention strategies, have improved patients' ability t%li%tolerate intensive treatments. This factor will help in the development of the global acute myeloid leukemia market.
Clinical Research and Innovation
Clinical research and innovative developments contribute t%li%the evolution of treatment approaches, the introduction of new therapies, and improved patient outcomes. Clinical research leads t%li%the discovery and development of new therapies, including targeted agents, immunotherapies, and other innovative treatment modalities. These novel therapies create new options for patients wh%li%may have exhausted traditional treatments. Through clinical trials, researchers can assess the efficacy of new treatments in comparison t%li%existing therapies. Positive outcomes from these trials lead t%li%increased adoption of the new treatments by healthcare providers, driving demand. Clinical research identifies genetic mutations and biomarkers associated with AML. This information enables personalized treatment approaches that target the specific characteristics of a patient's disease, increasing the demand for tailored therapies. Innovations in treatment contribute t%li%improved survival rates among AML patients. Positive outcomes from clinical trials and real-world data encourage healthcare providers t%li%adopt these treatments, increasing patient demand.
Robust clinical research attracts investments from pharmaceutical companies, biotech firms, and venture capitalists. The potential for innovative therapies in AML encourages funding and resources t%li%be directed toward the development of these treatments. The participation of AML patients in clinical trials provides access t%li%cutting-edge treatments that might not be available through standard care. This participation fosters patient demand for advanced therapies. Positive clinical trial outcomes often lead t%li%regulatory approvals by health authorities such as the FDA and EMA. These approvals legitimize new therapies and encourage their adoption in clinical practice. Clinical research findings are shared through medical conferences, publications, and educational programs. Healthcare providers learn about new treatment options and are more likely t%li%offer them t%li%their patients. International collaborations among researchers, institutions, and pharmaceutical companies accelerate the pace of innovation. The collective effort contributes t%li%the development of more effective treatments. Patients and advocacy groups are often strong advocates for clinical research and innovative treatments. Their efforts raise awareness, drive demand for research funding, and push for expedited access t%li%promising therapies. This factor will pace up the demand of the global acute myeloid leukemia market.
Awareness and Early Diagnosis
Early diagnosis allows for timely initiation of treatment, which can lead t%li%better treatment outcomes and increased chances of remission. As awareness spreads about the importance of early detection, more patients are likely t%li%seek medical attention promptly. Raising awareness about AML symptoms, risk factors, and the benefits of early diagnosis can lead t%li%a larger patient pool seeking medical evaluation. This, in turn, drives demand for diagnostic tests, treatments, and supportive care services. When AML is diagnosed at an earlier stage, patients may have a lower tumor burden, making treatments more effective. Early treatment can potentially reduce disease progression and the need for more aggressive therapies. Increased awareness may encourage individuals t%li%adopt healthier lifestyles and seek routine check-ups, helping t%li%identify potential risk factors and enabling early intervention t%li%prevent the development of AML.
Heightened awareness empowers patients t%li%recognize symptoms, communicate concerns with healthcare providers, and advocate for appropriate diagnostic tests and treatments. Awareness campaigns, educational programs, and patient advocacy efforts contribute t%li%educating the public, healthcare professionals, and policymakers about AML, its symptoms, and the importance of early diagnosis. Early diagnosis may lead t%li%less advanced disease stages, resulting in shorter hospital stays, fewer complications, and lower healthcare costs. This can drive healthcare systems t%li%invest in early detection and management programs. As awareness increases, funding for research and innovation in AML diagnosis and treatment may als%li%rise, stimulating advancements in diagnostics and therapies. International efforts t%li%promote cancer awareness and early diagnosis contribute t%li%the broader effort t%li%improve cancer care, including AML, on a global scale. In some cases, increased awareness about AML can lead t%li%the establishment of screening programs, allowing for early detection and intervention in high-risk populations. This factor will accelerate the demand of the global acute myeloid leukemia market.
Key Market Challenges
Lack of Biomarkers for Patient Stratification
Biomarkers are crucial indicators that help healthcare professionals predict disease behavior, determine treatment response, and tailor therapies t%li%individual patients. In AML, the absence of reliable biomarkers for accurate patient stratification can impact treatment decisions and outcomes. Biomarkers help guide treatment decisions by identifying patients wh%li%are likely t%li%respond t%li%specific therapies. Without effective biomarkers, treatments may be less targeted, potentially leading t%li%suboptimal outcomes. Biomarkers enable the development of targeted and personalized treatment strategies that are more effective and associated with fewer side effects. Biomarkers are essential in the development of new therapies. A lack of biomarkers can hinder the identification of patients wh%li%are most likely t%li%benefit from a new drug, leading t%li%challenges in clinical trial design and drug approvals. Biomarkers play a crucial role in patient enrollment and stratification in clinical trials. Without biomarkers, trials may include a heterogeneous patient population, making it challenging t%li%interpret trial results accurately. Lack of biomarkers can lead t%li%more generalized treatment guidelines rather than specific recommendations based on individual patient characteristics. The identification of biomarkers often directs research efforts toward understanding the underlying biology of AML, leading t%li%potential breakthroughs in treatment strategies.
Limited Availability of Stem Cell Donors
Stem cell transplantation, which includes bone marrow and hematopoietic stem cell transplantation, is a potentially curative treatment option for many AML patients. However, finding a compatible donor can be complex and challenging. Stem cell transplantation requires a compatible donor, usually a family member or an unrelated donor with matching tissue types. The chances of finding a suitable donor decrease as the genetic diversity between patients and potential donors increases. AML affects people from diverse ethnic backgrounds, and ethnicity plays a crucial role in finding a compatible donor. Patients from minority groups may face greater difficulty in finding a matched donor due t%li%the underrepresentation of certain ethnicities in donor registries. International registries of potential stem cell donors have been established t%li%improve donor matching. However, these registries still face challenges in achieving a diverse representation of donors from different populations. In cases where a fully matched donor cannot be found, haploidentical transplantation from a partially matched family member is an option. However, this procedure may carry higher risks. Umbilical cord blood contains stem cells and can be used for transplantation. Cord blood banks have been established t%li%provide another source of stem cells, but the quantity of cells in a single unit may not be sufficient for larger patients. AML treatment decisions are time-sensitive, and delays in finding a suitable donor can impact treatment outcomes and patient survival.
Key Market Trends
Patient Access and Affordability
Patient access and affordability are indeed important trends in the Global Acute Myeloid Leukemia (AML) Market. Ensuring that AML patients have access t%li%appropriate treatments and therapies without facing financial hardships is crucial for equitable and effective healthcare delivery. Patient access ensures that all individuals, regardless of their socioeconomic status, can receive timely and appropriate AML treatments. Addressing disparities in access contributes t%li%more equitable healthcare. Efforts t%li%improve patient access often involve expanding the availability of approved treatments, including novel therapies, targeted agents, and innovative treatment modalities. The high costs associated with AML treatment can be a barrier t%li%access. Market trends involve finding ways t%li%make treatments more affordable through pricing strategies, insurance coverage, and patient assistance programs. Government and healthcare regulatory bodies may implement policies t%li%enhance patient access and affordability, such as price controls or reimbursement adjustments for specific treatments. Ensuring that AML treatments are covered by insurance plans, including government-funded programs, can significantly improve patient access and alleviate financial burdens. Pharmaceutical companies and organizations often offer patient assistance programs that provide financial support t%li%eligible patients wh%li%may struggle with the cost of treatments.
Segmental Insights
Chemotherapy Insights
In 2023, the Cytarabine segment is witnessing highest growth and is predicted t%li%continue expanding over the coming years. Acute and chronic myelogenous leukaemia (AML and CML), acute lymphocytic leukaemia (ALL), and acute promyelocytic leukaemia (APL) are among the several leukaemia types that can be treated with cytarabine. Along with other lymphoma (cancers found in the lining of the brain and spinal cord), it can treat Hodgkin's lymphoma, meningeal leukaemia, and other forms of lymphoma. Cytarabine is frequently used during chemotherapy because it is useful in treating acute myeloid leukaemia. Cytarabine is frequently used because, according t%li%cancer organisations like Macmillan Cancer Support, it is more effective against acute myeloid leukaemia. As a result, it is anticipated that this sub-segment will account for a sizeable portion of the chemotherapy market.
Regional Insights
The North America region dominated the Global Acute Myeloid Leukemia Market in 2023. This market in this region is anticipated t%li%expand because of the increased incidence of acute myeloid leukaemia cases in the US. For instance, acute myeloid leukaemia is a rare cancer that makes up about 1% of all malignancies, according t%li%the American Society of Clinical Oncology in 2021. In the US, this disease was thought t%li%have affected 20,240 persons of all ages in 2021 (11,230 men and boys and 9,010 women and girls). AML is the second most common kind of leukaemia in both adults and children, with cases primarily affecting adults. Since acute myeloid leukaemia is becoming more common in the US, more people will likely use its treatments, which is predicted t%li%fuel the market's expansion in North America. Rising R&D spending and new product introductions for acute myeloid leukaemia are als%li%anticipated t%li%fuel market expansion in this area.
Due t%li%the expansion of government initiatives t%li%raise public awareness, an increase in medical tourism, an increase in research activities in the region, the availability of sizable untapped markets, a sizable population pool, and the rising demand for high-quality healthcare in the region, Asia-Pacific is predicted t%li%experience significant growth during the forecast period of 2023 t%li%2030.
Key Market Players
In this report, the Global Acute Myeloid Leukemia Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Acute Myeloid Leukemia Market.
Available Customizations:
Global Acute Myeloid Leukemia Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. It is characterized by the rapid growth of abnormal myeloid cells, which are immature white blood cells responsible for fighting infections and carrying oxygen. In AML, these abnormal cells d%li%not mature properly and crowd out healthy cells in the bone marrow, leading t%li%a decrease in the production of normal blood cells. This can result in a variety of symptoms and complications. AML can cause a range of symptoms, including fatigue, weakness, anemia (low red blood cell count), increased susceptibility t%li%infections, bleeding or bruising easily (due t%li%low platelet count), fever, and weight loss. Some patients may als%li%experience bone pain. The development of new and improved therapies, including targeted therapies and immunotherapies, has expanded the treatment options available for AML patients. These advancements provide more effective and personalized treatment approaches.
Ongoing research and development efforts in the field of AML have led t%li%the discovery of novel therapeutic targets and treatment strategies. This innovation attracts investment and drives the market forward. Advances in molecular diagnostics have enabled the identification of specific genetic mutations and markers associated with AML. This has paved the way for personalized treatment approaches, increasing the demand for targeted therapies. Regulatory agencies approving new therapies for AML treatment contribute t%li%market growth by expanding the available treatment options and improving patient outcomes. Improved awareness of AML symptoms and the importance of early diagnosis has led t%li%more patients seeking treatment at an earlier stage, potentially improving outcomes, and driving demand for therapies.
Key Market Drivers
Advancements in Treatment Options
The development of targeted therapies that focus on specific genetic mutations or molecular markers associated with AML has been a breakthrough. Drugs like 'FLT3 inhibitors' and 'IDH inhibitors' target specific mutations in leukemia cells, leading t%li%more effective and tailored treatments. Immunotherapies, including monoclonal antibodies and checkpoint inhibitors, are being explored for their potential in AML treatment. These therapies harness the body's immune system t%li%recognize and attack leukemia cells. The rise of precision medicine involves tailoring treatment based on a patient's unique genetic and molecular profile. This approach allows for personalized treatment strategies that have the potential t%li%be more effective and less toxic.
Epigenetic changes play a significant role in AML development. Drugs that target these changes, such as 'DNMT inhibitors' and 'HDAC inhibitors,' are being studied as potential treatments. Venetoclax, an inhibitor of BCL-2, has shown promise in combination with other therapies, particularly in older adults or those with certain genetic mutations. Advances in detecting very low levels of leukemia cells, known as MRD, have allowed for more accurate assessment of treatment response and adjustment of treatment strategies accordingly. Techniques for stem cell transplantation have improved, expanding the eligibility criteria, and reducing complications associated with the procedure. Researchers are investigating various combinations of chemotherapy, targeted therapies, and immunotherapies t%li%enhance treatment efficacy while minimizing side effects. Advances in supportive care, such as anti-nausea medications and infection prevention strategies, have improved patients' ability t%li%tolerate intensive treatments. This factor will help in the development of the global acute myeloid leukemia market.
Clinical Research and Innovation
Clinical research and innovative developments contribute t%li%the evolution of treatment approaches, the introduction of new therapies, and improved patient outcomes. Clinical research leads t%li%the discovery and development of new therapies, including targeted agents, immunotherapies, and other innovative treatment modalities. These novel therapies create new options for patients wh%li%may have exhausted traditional treatments. Through clinical trials, researchers can assess the efficacy of new treatments in comparison t%li%existing therapies. Positive outcomes from these trials lead t%li%increased adoption of the new treatments by healthcare providers, driving demand. Clinical research identifies genetic mutations and biomarkers associated with AML. This information enables personalized treatment approaches that target the specific characteristics of a patient's disease, increasing the demand for tailored therapies. Innovations in treatment contribute t%li%improved survival rates among AML patients. Positive outcomes from clinical trials and real-world data encourage healthcare providers t%li%adopt these treatments, increasing patient demand.
Robust clinical research attracts investments from pharmaceutical companies, biotech firms, and venture capitalists. The potential for innovative therapies in AML encourages funding and resources t%li%be directed toward the development of these treatments. The participation of AML patients in clinical trials provides access t%li%cutting-edge treatments that might not be available through standard care. This participation fosters patient demand for advanced therapies. Positive clinical trial outcomes often lead t%li%regulatory approvals by health authorities such as the FDA and EMA. These approvals legitimize new therapies and encourage their adoption in clinical practice. Clinical research findings are shared through medical conferences, publications, and educational programs. Healthcare providers learn about new treatment options and are more likely t%li%offer them t%li%their patients. International collaborations among researchers, institutions, and pharmaceutical companies accelerate the pace of innovation. The collective effort contributes t%li%the development of more effective treatments. Patients and advocacy groups are often strong advocates for clinical research and innovative treatments. Their efforts raise awareness, drive demand for research funding, and push for expedited access t%li%promising therapies. This factor will pace up the demand of the global acute myeloid leukemia market.
Awareness and Early Diagnosis
Early diagnosis allows for timely initiation of treatment, which can lead t%li%better treatment outcomes and increased chances of remission. As awareness spreads about the importance of early detection, more patients are likely t%li%seek medical attention promptly. Raising awareness about AML symptoms, risk factors, and the benefits of early diagnosis can lead t%li%a larger patient pool seeking medical evaluation. This, in turn, drives demand for diagnostic tests, treatments, and supportive care services. When AML is diagnosed at an earlier stage, patients may have a lower tumor burden, making treatments more effective. Early treatment can potentially reduce disease progression and the need for more aggressive therapies. Increased awareness may encourage individuals t%li%adopt healthier lifestyles and seek routine check-ups, helping t%li%identify potential risk factors and enabling early intervention t%li%prevent the development of AML.
Heightened awareness empowers patients t%li%recognize symptoms, communicate concerns with healthcare providers, and advocate for appropriate diagnostic tests and treatments. Awareness campaigns, educational programs, and patient advocacy efforts contribute t%li%educating the public, healthcare professionals, and policymakers about AML, its symptoms, and the importance of early diagnosis. Early diagnosis may lead t%li%less advanced disease stages, resulting in shorter hospital stays, fewer complications, and lower healthcare costs. This can drive healthcare systems t%li%invest in early detection and management programs. As awareness increases, funding for research and innovation in AML diagnosis and treatment may als%li%rise, stimulating advancements in diagnostics and therapies. International efforts t%li%promote cancer awareness and early diagnosis contribute t%li%the broader effort t%li%improve cancer care, including AML, on a global scale. In some cases, increased awareness about AML can lead t%li%the establishment of screening programs, allowing for early detection and intervention in high-risk populations. This factor will accelerate the demand of the global acute myeloid leukemia market.
Key Market Challenges
Lack of Biomarkers for Patient Stratification
Biomarkers are crucial indicators that help healthcare professionals predict disease behavior, determine treatment response, and tailor therapies t%li%individual patients. In AML, the absence of reliable biomarkers for accurate patient stratification can impact treatment decisions and outcomes. Biomarkers help guide treatment decisions by identifying patients wh%li%are likely t%li%respond t%li%specific therapies. Without effective biomarkers, treatments may be less targeted, potentially leading t%li%suboptimal outcomes. Biomarkers enable the development of targeted and personalized treatment strategies that are more effective and associated with fewer side effects. Biomarkers are essential in the development of new therapies. A lack of biomarkers can hinder the identification of patients wh%li%are most likely t%li%benefit from a new drug, leading t%li%challenges in clinical trial design and drug approvals. Biomarkers play a crucial role in patient enrollment and stratification in clinical trials. Without biomarkers, trials may include a heterogeneous patient population, making it challenging t%li%interpret trial results accurately. Lack of biomarkers can lead t%li%more generalized treatment guidelines rather than specific recommendations based on individual patient characteristics. The identification of biomarkers often directs research efforts toward understanding the underlying biology of AML, leading t%li%potential breakthroughs in treatment strategies.
Limited Availability of Stem Cell Donors
Stem cell transplantation, which includes bone marrow and hematopoietic stem cell transplantation, is a potentially curative treatment option for many AML patients. However, finding a compatible donor can be complex and challenging. Stem cell transplantation requires a compatible donor, usually a family member or an unrelated donor with matching tissue types. The chances of finding a suitable donor decrease as the genetic diversity between patients and potential donors increases. AML affects people from diverse ethnic backgrounds, and ethnicity plays a crucial role in finding a compatible donor. Patients from minority groups may face greater difficulty in finding a matched donor due t%li%the underrepresentation of certain ethnicities in donor registries. International registries of potential stem cell donors have been established t%li%improve donor matching. However, these registries still face challenges in achieving a diverse representation of donors from different populations. In cases where a fully matched donor cannot be found, haploidentical transplantation from a partially matched family member is an option. However, this procedure may carry higher risks. Umbilical cord blood contains stem cells and can be used for transplantation. Cord blood banks have been established t%li%provide another source of stem cells, but the quantity of cells in a single unit may not be sufficient for larger patients. AML treatment decisions are time-sensitive, and delays in finding a suitable donor can impact treatment outcomes and patient survival.
Key Market Trends
Patient Access and Affordability
Patient access and affordability are indeed important trends in the Global Acute Myeloid Leukemia (AML) Market. Ensuring that AML patients have access t%li%appropriate treatments and therapies without facing financial hardships is crucial for equitable and effective healthcare delivery. Patient access ensures that all individuals, regardless of their socioeconomic status, can receive timely and appropriate AML treatments. Addressing disparities in access contributes t%li%more equitable healthcare. Efforts t%li%improve patient access often involve expanding the availability of approved treatments, including novel therapies, targeted agents, and innovative treatment modalities. The high costs associated with AML treatment can be a barrier t%li%access. Market trends involve finding ways t%li%make treatments more affordable through pricing strategies, insurance coverage, and patient assistance programs. Government and healthcare regulatory bodies may implement policies t%li%enhance patient access and affordability, such as price controls or reimbursement adjustments for specific treatments. Ensuring that AML treatments are covered by insurance plans, including government-funded programs, can significantly improve patient access and alleviate financial burdens. Pharmaceutical companies and organizations often offer patient assistance programs that provide financial support t%li%eligible patients wh%li%may struggle with the cost of treatments.
Segmental Insights
Chemotherapy Insights
In 2023, the Cytarabine segment is witnessing highest growth and is predicted t%li%continue expanding over the coming years. Acute and chronic myelogenous leukaemia (AML and CML), acute lymphocytic leukaemia (ALL), and acute promyelocytic leukaemia (APL) are among the several leukaemia types that can be treated with cytarabine. Along with other lymphoma (cancers found in the lining of the brain and spinal cord), it can treat Hodgkin's lymphoma, meningeal leukaemia, and other forms of lymphoma. Cytarabine is frequently used during chemotherapy because it is useful in treating acute myeloid leukaemia. Cytarabine is frequently used because, according t%li%cancer organisations like Macmillan Cancer Support, it is more effective against acute myeloid leukaemia. As a result, it is anticipated that this sub-segment will account for a sizeable portion of the chemotherapy market.
Regional Insights
The North America region dominated the Global Acute Myeloid Leukemia Market in 2023. This market in this region is anticipated t%li%expand because of the increased incidence of acute myeloid leukaemia cases in the US. For instance, acute myeloid leukaemia is a rare cancer that makes up about 1% of all malignancies, according t%li%the American Society of Clinical Oncology in 2021. In the US, this disease was thought t%li%have affected 20,240 persons of all ages in 2021 (11,230 men and boys and 9,010 women and girls). AML is the second most common kind of leukaemia in both adults and children, with cases primarily affecting adults. Since acute myeloid leukaemia is becoming more common in the US, more people will likely use its treatments, which is predicted t%li%fuel the market's expansion in North America. Rising R&D spending and new product introductions for acute myeloid leukaemia are als%li%anticipated t%li%fuel market expansion in this area.
Due t%li%the expansion of government initiatives t%li%raise public awareness, an increase in medical tourism, an increase in research activities in the region, the availability of sizable untapped markets, a sizable population pool, and the rising demand for high-quality healthcare in the region, Asia-Pacific is predicted t%li%experience significant growth during the forecast period of 2023 t%li%2030.
Key Market Players
- Bristol-Myers Squibb Company (Celgene Corporation)
- Novartis AG
- Genmab AS
- Otsuka Holdings Co. Ltd
- Sanofi-Aventis (Genzyme Corporation)
- Teva Pharmaceutical (Cephalon Inc.)
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sunesis Pharmaceuticals Inc.
- Astellas Pharma
- Oncolyze Inc.
- Syndax Pharmaceuticals Inc.
- AbbVie Inc.
- Amgen Inc.
- Agios Pharmaceuticals Inc.
In this report, the Global Acute Myeloid Leukemia Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- Acute Myeloid Leukemia Market, By Chemotherapy:
- Cytarabine
- Anthracycline Drugs
- Alkylating Agents
- Anti-metabolites
- Tyrosine Kinase Inhibitors
- Hormonal therapy
- Other chemotherapies
- Acute Myeloid Leukemia Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Acute Myeloid Leukemia Market.
Available Customizations:
Global Acute Myeloid Leukemia Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. IMPACT OF COVID-19 ON GLOBAL ACUTE MYELOID LEUKEMIA MARKET
5. VOICE OF CUSTOMER
6. GLOBAL ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies)
6.2.2. By Region
6.2.3. By Company (2023)
6.3. Market Map
7. ASIA PACIFIC ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Chemotherapy
7.2.2. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Acute Myeloid Leukemia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Chemotherapy
7.3.2. India Acute Myeloid Leukemia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Chemotherapy
7.3.3. Australia Acute Myeloid Leukemia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Chemotherapy
7.3.4. Japan Acute Myeloid Leukemia Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Chemotherapy
7.3.5. South Korea Acute Myeloid Leukemia Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Chemotherapy
8. EUROPE ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Chemotherapy
8.2.2. By Country
8.3. Europe: Country Analysis
8.3.1. France Acute Myeloid Leukemia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Chemotherapy
8.3.2. Germany Acute Myeloid Leukemia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Chemotherapy
8.3.3. Spain Acute Myeloid Leukemia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Chemotherapy
8.3.4. Italy Acute Myeloid Leukemia Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Chemotherapy
8.3.5. United Kingdom Acute Myeloid Leukemia Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Chemotherapy
9. NORTH AMERICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Chemotherapy
9.2.2. By Country
9.3. North America: Country Analysis
9.3.1. United States Acute Myeloid Leukemia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Chemotherapy
9.3.2. Mexico Acute Myeloid Leukemia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Chemotherapy
9.3.3. Canada Acute Myeloid Leukemia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Chemotherapy
10. SOUTH AMERICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Chemotherapy
10.2.2. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Chemotherapy
10.3.2. Argentina Acute Myeloid Leukemia Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Chemotherapy
10.3.3. Colombia Acute Myeloid Leukemia Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Chemotherapy
11. MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Chemotherapy
11.2.2. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Acute Myeloid Leukemia Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Chemotherapy
11.3.2. Saudi Arabia Acute Myeloid Leukemia Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Chemotherapy
11.3.3. UAE Acute Myeloid Leukemia Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Chemotherapy
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. GLOBAL ACUTE MYELOID LEUKEMIA MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. PESTLE ANALYSIS
17. COMPETITIVE LANDSCAPE
17.1. Bristol-Myers Squibb Company (Celgene Corporation)
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (In case of listed companies)
17.1.5. Recent Developments
17.1.6. SWOT Analysis
17.2. Novartis AG
17.3. Genmab AS
17.4. Otsuka Holdings Co. Ltd
17.5. Sanofi-Aventis (Genzyme Corporation)
17.6. Teva Pharmaceutical (Cephalon Inc.)
17.7. Pfizer Inc.
17.8. F. Hoffmann-La Roche Ltd
17.9. Sunesis Pharmaceuticals Inc.
17.10. Astellas Pharma
17.11. Oncolyze Inc.
17.12. Syndax Pharmaceuticals Inc.
17.13. AbbVie Inc.
17.14. Amgen Inc.
17.15. Agios Pharmaceuticals Inc.
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. IMPACT OF COVID-19 ON GLOBAL ACUTE MYELOID LEUKEMIA MARKET
5. VOICE OF CUSTOMER
6. GLOBAL ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies)
6.2.2. By Region
6.2.3. By Company (2023)
6.3. Market Map
7. ASIA PACIFIC ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Chemotherapy
7.2.2. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Acute Myeloid Leukemia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Chemotherapy
7.3.2. India Acute Myeloid Leukemia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Chemotherapy
7.3.3. Australia Acute Myeloid Leukemia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Chemotherapy
7.3.4. Japan Acute Myeloid Leukemia Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Chemotherapy
7.3.5. South Korea Acute Myeloid Leukemia Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Chemotherapy
8. EUROPE ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Chemotherapy
8.2.2. By Country
8.3. Europe: Country Analysis
8.3.1. France Acute Myeloid Leukemia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Chemotherapy
8.3.2. Germany Acute Myeloid Leukemia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Chemotherapy
8.3.3. Spain Acute Myeloid Leukemia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Chemotherapy
8.3.4. Italy Acute Myeloid Leukemia Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Chemotherapy
8.3.5. United Kingdom Acute Myeloid Leukemia Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Chemotherapy
9. NORTH AMERICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Chemotherapy
9.2.2. By Country
9.3. North America: Country Analysis
9.3.1. United States Acute Myeloid Leukemia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Chemotherapy
9.3.2. Mexico Acute Myeloid Leukemia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Chemotherapy
9.3.3. Canada Acute Myeloid Leukemia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Chemotherapy
10. SOUTH AMERICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Chemotherapy
10.2.2. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Chemotherapy
10.3.2. Argentina Acute Myeloid Leukemia Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Chemotherapy
10.3.3. Colombia Acute Myeloid Leukemia Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Chemotherapy
11. MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Chemotherapy
11.2.2. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Acute Myeloid Leukemia Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Chemotherapy
11.3.2. Saudi Arabia Acute Myeloid Leukemia Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Chemotherapy
11.3.3. UAE Acute Myeloid Leukemia Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Chemotherapy
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. GLOBAL ACUTE MYELOID LEUKEMIA MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. PESTLE ANALYSIS
17. COMPETITIVE LANDSCAPE
17.1. Bristol-Myers Squibb Company (Celgene Corporation)
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (In case of listed companies)
17.1.5. Recent Developments
17.1.6. SWOT Analysis
17.2. Novartis AG
17.3. Genmab AS
17.4. Otsuka Holdings Co. Ltd
17.5. Sanofi-Aventis (Genzyme Corporation)
17.6. Teva Pharmaceutical (Cephalon Inc.)
17.7. Pfizer Inc.
17.8. F. Hoffmann-La Roche Ltd
17.9. Sunesis Pharmaceuticals Inc.
17.10. Astellas Pharma
17.11. Oncolyze Inc.
17.12. Syndax Pharmaceuticals Inc.
17.13. AbbVie Inc.
17.14. Amgen Inc.
17.15. Agios Pharmaceuticals Inc.
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
